FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average burden									
hours per response.	0.5								

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Geffken Daniel E.				2. Issuer Name and Ticker or Trading Symbol Eloxx Pharmaceuticals, Inc. [ELOX]						(Ch	elationship o eck all applica Director	able)	g Pers	on(s) to Issu 10% Ov Other (s	vner		
(Last) (First) (Middle) C/O ELOXX PHARMACEUTICALS, INC. 950 WINTER STREET				3. Date of Earliest Transaction (Month/Day/Year) 04/20/2021						below)				·			
(Street) WALTH	AM M	IA .	02451 (Zip)		4. If Amendment, Date of Original Filed (Month/Da	y/Year)	Line	Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																	
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)				Execution Date,		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4)			5. Amoun Securities Beneficia Owned Fo	s lly ollowing	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
			Code			v	Amount	(A) o (D)	r Price	Transacti (Instr. 3 a	on(s)						
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																	
1. Title of Derivative Security (Instr. 3)	perivative Conversion Date Execution Date, or Exercise (Month/Day/Year) if any Co			nsaction Derivative			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Am of Securities Underlying Derivative Secu (Instr. 3 and 4)			ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Cod	ie V	(A)		Date Exercisable		cpiration ate	Title	Amount or Number of Shares		(Instr. 4)	ion(s)		
Non- Qualified Stock Option (right to buy)	\$2.38	04/20/2021		A		100,000		(1)	04	1/20/2026	Common Stock	100,000	\$0	100,00	00	D ⁽²⁾	

Explanation of Responses:

1. The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan and vests as follows: ratably on a monthly basis on the last calendar day of each month during the first twelve (12) months following the grant date; provided, however, that if the Issuer terminates the Consulting Agreement for the reporting person's services or if the reporting person is no longer servicing the Issuer at any time following the grant date, no further options shall vest following such termination. If the Consulting Agreement or if the services of the reporting person are terminated for cause by the Issuer, then the options shall be forfeited

2. The reporting person will assign the economic interest of this grant to Danforth Advisors, LLC, where he serves as Managing Director.

/s/ Neil S. Belloff, Attorney-in-

Fact

04/22/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.